Login
$XLO
$7.70 -$0.37 (4.64%) Live

$XLO SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
13 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 SCHEDULE 13G
10 Nov 2026 S-8
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027

02 Oct 2026 Form 4: Houvras Yariv, CHIEF MEDICAL OFFICER

Granted 105,000 Stock Option (right to buy)

02 Oct 2026 Form 3: Houvras Yariv, CHIEF MEDICAL OFFICER

No securities owned

14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 S-8
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

12 Jun 2026 Form 4: Bello Akintunde Olatokumbo, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Shannon James Samuel, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Curran Daniel J., Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Xu Yuan, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Ross Robert W., Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Bonstein Sara, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 Form 4: Brennan Aoife, Director

Granted 5,000 Stock Option (right to buy)

12 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

In order to achieve a more equal balance of director membership among the three classes of the board of directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) in accordance with the Company’s Restated Certificate of Incorpor...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support